Overview
Company Does Not Provide H-1B Sponsorship
IONLACE is a biotech-focused R&D company that builds and funds science projects in biotechnology, molecular biology, and advanced materials. It hires highly skilled, highly curious scientists—“rebel scientists”—and gives them resources and freedom to pursue ambitious, real-world-impact ideas. The company operates in innovation hubs like Stockholm and Copenhagen to accelerate research and development. Revenue comes from advancing R&D projects toward commercialization through patents, partnerships with larger companies, and market-ready products, as well as grants and venture funding. IONLACE differentiates itself by prioritizing rapid execution and bold, high-risk research led by top talent, aiming to stay ahead in a competitive field. Its goal is to shape the future of scientific and technological progress by turning breakthroughs into practical applications through collaborations, licensing, and new products.
Work here?Claim your company
Simplify's take
What believers are saying
- Mats Berggren said in November 2026 IONLACE has $4M from US and EU investors.
- Active hiring in October-November 2026 suggests runway and ongoing product development.
- Built In and LinkedIn show a ten-person team spanning AI, lab automation, and protein biology.
What critics are saying
- No peer-reviewed data or commercial partnerships are public, so customers cannot validate platform performance.
- Small 10-person team and deeptech biology scope risk execution slippage before 2027.
- If fundraising stalls, IONLACE's lab-heavy model dies because cash burn outruns revenue.
What makes Ionlace unique
- IONLACE combines AI and synthetic biology through lab-in-the-loop biologics design at Karolinska.
- It hires for modular protein design and agentic AI, signaling a tightly integrated platform.
- Stockholm-Cambridge footprint gives access to Nordic biology talent and UK research networks.
Help us improve and share your feedback! Did you find this helpful?